Manon van Engeland

Summary

Country: The Netherlands

Publications

  1. ncbi Colorectal cancer epigenetics: complex simplicity
    Manon van Engeland
    GROW School for Oncology and Developmental Biology, PO Box 616, 6200 Maastricht, The Netherlands
    J Clin Oncol 29:1382-91. 2011
  2. ncbi Viewing the epigenetics of colorectal cancer through the window of folic acid effects
    Manon van Engeland
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Cancer Prev Res (Phila) 3:1509-12. 2010
  3. ncbi Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer
    Stefan de Vogel
    Department of Epidemiology, GROW, School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Carcinogenesis 29:1765-73. 2008
  4. ncbi Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?
    Eddy H J van Roon
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Cancer 10:180. 2010
  5. ncbi Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer
    Stefan de Vogel
    Departments of Epidemiology, GROW School for Oncology and Developmental Biology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Cancer Epidemiol Biomarkers Prev 18:3086-96. 2009
  6. ncbi N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer
    Veerle Melotte
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands
    J Natl Cancer Inst 101:916-27. 2009
  7. ncbi Dietary folate and APC mutations in sporadic colorectal cancer
    Stefan de Vogel
    Research Institute Growth and Development GROW, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
    J Nutr 136:3015-21. 2006
  8. ncbi Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21
    Sarah Derks
    Department of Pathology, Maastricht University Medical Center, The Netherlands
    Carcinogenesis 30:1041-8. 2009
  9. ncbi Identification of epigenetically silenced genes in tumor endothelial cells
    Debby M E I Hellebrekers
    Department of Pathology, Research Institute for Growth and Development, Maastricht University and University Hospital, Maastricht, The Netherlands
    Cancer Res 67:4138-48. 2007
  10. ncbi Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection
    Linda J W Bosch
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol (Dordr) 35:309-15. 2012

Collaborators

Detail Information

Publications50

  1. ncbi Colorectal cancer epigenetics: complex simplicity
    Manon van Engeland
    GROW School for Oncology and Developmental Biology, PO Box 616, 6200 Maastricht, The Netherlands
    J Clin Oncol 29:1382-91. 2011
    ..This review integrates recent data on epigenetic regulation of gene expression in CRC and describes how the understanding of these processes will alter the management of CRC...
  2. ncbi Viewing the epigenetics of colorectal cancer through the window of folic acid effects
    Manon van Engeland
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Cancer Prev Res (Phila) 3:1509-12. 2010
    ..This perspective will place this study in context, looking at what it tells us and what it does not...
  3. ncbi Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer
    Stefan de Vogel
    Department of Epidemiology, GROW, School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Carcinogenesis 29:1765-73. 2008
    ....
  4. ncbi Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?
    Eddy H J van Roon
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    BMC Cancer 10:180. 2010
    ..As this type of colon cancer is associated with high ages, young patients bearing this type of malignancy are rare and could provide additional insight into the etiology of sporadic MSI-H colon cancer...
  5. ncbi Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer
    Stefan de Vogel
    Departments of Epidemiology, GROW School for Oncology and Developmental Biology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Cancer Epidemiol Biomarkers Prev 18:3086-96. 2009
    ..The incomplete overlap between CIMP, MLH1 hypermethylation, and microsatellite instability indicates that these related "methylation phenotypes" may not be similar and should be investigated separately...
  6. ncbi N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer
    Veerle Melotte
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands
    J Natl Cancer Inst 101:916-27. 2009
    ..Here we examined the role of N-Myc downstream-regulated gene 4 (NDRG4) as a novel tumor suppressor and biomarker in colorectal cancer...
  7. ncbi Dietary folate and APC mutations in sporadic colorectal cancer
    Stefan de Vogel
    Research Institute Growth and Development GROW, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
    J Nutr 136:3015-21. 2006
    ..These opposite results may indicate that folate enhances colorectal carcinogenesis through a distinct APC mutated pathway...
  8. ncbi Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21
    Sarah Derks
    Department of Pathology, Maastricht University Medical Center, The Netherlands
    Carcinogenesis 30:1041-8. 2009
    ..Only active epigenetic marks were detected for MBD1, CXXC1, SMAD4 and MBD2. This study demonstrates specific epigenetic silencing of DCC in CRC as a focal process not affecting neighboring genes on chromosomal region 18q21...
  9. ncbi Identification of epigenetically silenced genes in tumor endothelial cells
    Debby M E I Hellebrekers
    Department of Pathology, Research Institute for Growth and Development, Maastricht University and University Hospital, Maastricht, The Netherlands
    Cancer Res 67:4138-48. 2007
    ....
  10. ncbi Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection
    Linda J W Bosch
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol (Dordr) 35:309-15. 2012
    ..In addition, we explored the detection of DNA methylation in fecal immunochemical test (FIT) fluid...
  11. ncbi A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer
    Kim M Smits
    Departments of Pathology and Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Clin Cancer Res 17:7723-31. 2011
    ..Effects in early-stage CRC are however unknown. We studied KRAS-LCS6 genotype, hypothesizing that it might identify early-stage cases with a poor prognosis, and could potentially be used in therapy decision-making...
  12. ncbi Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms
    Laura A E Hughes
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    PLoS ONE 4:e7951. 2009
    ..Within the Netherlands Cohort Study on diet and cancer, we investigated the association between early life energy restriction and risk of subsequent CRC characterized by the (promoter) CpG island methylation phenotype (CIMP)...
  13. ncbi Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma
    Leo J Schouten
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, P O Box 616, 6200 MD Maastricht, The Netherlands
    Cancer Epidemiol Biomarkers Prev 17:3543-50. 2008
    ..58; 95% CI, 0.34-0.99). In this study, a not statistically significant inverse association was observed between alcohol and renal cell cancer. There was no statistical significant heterogeneity by VHL mutation or methylation status...
  14. ncbi Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications
    Debby M E I Hellebrekers
    Angiogenesis Laboratory, Research Institute for Growth and Development, Department of Pathology, Maastricht University and University Hospital, The Netherlands
    Cancer Res 66:10770-7. 2006
    ....
  15. ncbi Alcohol consumption, alcohol dehydrogenase 1C (ADH1C) genotype, and risk of colorectal cancer in the Netherlands Cohort Study on diet and cancer
    Brenda W C Bongaerts
    GROW School for Oncology and Developmental Biology, Department of Epidemiology, Maastricht University, The Netherlands
    Alcohol 45:217-25. 2011
    ..Nevertheless, the interaction deserves further investigation in larger genetic epidemiologic studies...
  16. ncbi Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations
    Sarah Derks
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, 6200 MD, The Netherlands
    Carcinogenesis 29:434-9. 2008
    ..Therefore, we conclude that promoter methylation of pivotal tumour suppressor and DNA repair genes is associated with specific patterns of chromosomal changes in CRC, which are different from methylation patterns in MSI tumours...
  17. ncbi Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study
    Mirian Brink
    Research Institute Nutrition and Toxicology Research Institute Maastricht (NUTRIM, Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
    Int J Cancer 114:824-30. 2005
    ..09), but inversely associated with G>A transitions (RR = 0.08, 95% CI = 0.01-0.53). Our data suggest that the effect of folate on rectal cancer risk is different for men and women and depends on the K-ras mutation status of the tumor...
  18. ncbi Body size and colorectal cancer risk after 16.3 years of follow-up: an analysis from the Netherlands Cohort Study
    Laura A E Hughes
    Department of Epidemiology, Faculty of Health Medicine and Life Science, MaastrichtUniversity, Maastricht, The Netherlands
    Am J Epidemiol 174:1127-39. 2011
    ..Height was associated with risk of CRC, especially distal colon tumors (highest quintile vs. lowest: HR = 1.53, 95% CI: 1.03, 2.27; P-trend = 0.05), in women only...
  19. ncbi DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT
    Linda J W Bosch
    Department of Pathology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands
    Cancer Prev Res (Phila) 5:464-72. 2012
    ..Adding PHACTR3 methylation to FIT increased sensitivity for CRC up to 15%. PHACTR3 is a new hypermethylated gene in CRC with a good performance in stool DNA testing and has complementary value to FIT...
  20. ncbi Dietary folate, methionine, riboflavin, and vitamin B-6 and risk of sporadic colorectal cancer
    Stefan de Vogel
    Departments of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    J Nutr 138:2372-8. 2008
    ..This is the 2nd prospective cohort study in which vitamin B-6 intake was associated with increased risk of rectal tumors in women, which might suggest that this vitamin enhances rectal cancer in women...
  21. ncbi The CpG island methylator phenotype in colorectal cancer: progress and problems
    Laura A E Hughes
    Dept of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6200MD Maastricht, The Netherlands
    Biochim Biophys Acta 1825:77-85. 2012
    ....
  22. ncbi GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer
    Debby M E I Hellebrekers
    Departments of Pathology and Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Clin Cancer Res 15:3990-7. 2009
    ..Here, we evaluated GATA4/5 promoter methylation as potential biomarkers for noninvasive colorectal cancer detection, and investigated the role of GATA4/5 in colorectal cancer...
  23. ncbi Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP)
    Laura A E Hughes
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    PLoS ONE 6:e18571. 2011
    ..We investigated how body size and physical activity influence the risk of the CpG island methylator phenotype (CIMP) in colorectal cancer (CRC)...
  24. ncbi Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma
    Iris J H van Vlodrop
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, PO Box 616, 6200 MD Maastricht, The Netherlands
    Am J Pathol 176:575-84. 2010
    ..59, respectively). The strong correlation between GREM1 region iii promoter methylation and increased malignancy and its correlation with active angiogenesis indicates a role for GREM1 in ccRCC carcinogenesis and tumor angiogenesis...
  25. ncbi VHL and HIF signalling in renal cell carcinogenesis
    Marcella M Baldewijns
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
    J Pathol 221:125-38. 2010
    ..In this review, we discuss existing and novel findings about RCC carcinogenesis, with subsequent clinical implications...
  26. ncbi Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene
    Marcella M Baldewijns
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Cell Oncol 31:371-82. 2009
    ....
  27. ncbi Promoter CpG island methylation markers in colorectal cancer: the road ahead
    Muriel X G Draht
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Epigenomics 4:179-94. 2012
    ..This review summarizes the current knowledge of hypermethylation biomarkers for CRC detection, progression and treatment outcome...
  28. ncbi Childhood and adolescent energy restriction and subsequent colorectal cancer risk: results from the Netherlands Cohort Study
    Laura A E Hughes
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Int J Epidemiol 39:1333-44. 2010
    ..Energy restriction during childhood and adolescence is suggested to lower colorectal cancer (CRC) risk. We investigated this in the Netherlands Cohort Study...
  29. ncbi Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer
    Manon van Engeland
    The Research Institute GROW, Department of Pathology, University Maastricht, 6200 MD Maastricht, The Netherlands
    Cancer Res 63:3133-7. 2003
    ..085). Despite the size limitations of this study, these data suggest that folate and alcohol intake may be associated with changes in promoter hypermethylation in CRC...
  30. ncbi Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis
    Kim M Smits
    Departmens of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Clin Cancer Res 14:782-7. 2008
    ..We have evaluated the influence of (epi)genetic alterations in VHL on cause-specific survival in clear-cell renal cell cancer (ccRCC) in a large, population-based group of cases...
  31. ncbi Analysis of promoter CpG island hypermethylation in cancer: location, location, location!
    Iris J H van Vlodrop
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Clin Cancer Res 17:4225-31. 2011
    ..Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer...
  32. ncbi The adenoma hunt in colorectal cancer screening: defining the target
    Anke H Sillars-Hardebol
    Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands
    J Pathol 226:1-6. 2012
    ..Screening tests based on genomic changes that affect relevant biological and metabolic processes hold most promise in this respect...
  33. ncbi Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas
    Carolina A J Khalid-de Bakker
    Division of Gastroenterology Hepatology, Department of Internal Medicine, Maastricht University Medical Center, The Netherlands
    Cancer Prev Res (Phila) 4:1563-71. 2011
    ..This points to the existence of "low" FIT performance in subgroups and the need for more tailored screening strategies...
  34. ncbi Methylation-specific PCR unraveled
    Sarah Derks
    Research Institute GROW, Department of Pathology, University Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands
    Cell Oncol 26:291-9. 2004
    ..This review discusses the critical parameters of MSP and presents an overview of the available MSP variants and the (clinical) applications...
  35. ncbi Dual targeting of epigenetic therapy in cancer
    Debby M E I Hellebrekers
    Tumor Biology Laboratory, Research Institute for Growth and Development GROW, Department of Pathology, Maastricht University and University Hospital Maastricht, Maastricht, The Netherlands
    Biochim Biophys Acta 1775:76-91. 2007
    ..Here we review the therapeutic potential of DNMT and HDAC inhibitors as anti-cancer drugs, as evaluated in clinical trials, and their angiostatic activities, apart from their inhibitory effects on tumor cells...
  36. ncbi Comprehensive mutation analysis in colorectal flat adenomas
    Quirinus J M Voorham
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    PLoS ONE 7:e41963. 2012
    ..In the present study, we aimed to compare the mutation spectrum of 14 cancer genes, between these two phenotypes...
  37. ncbi Promoter methylation precedes chromosomal alterations in colorectal cancer development
    Sarah Derks
    Department of Pathology, Research Institute GROW, University Maastricht, The Netherlands
    Cell Oncol 28:247-57. 2006
    ....
  38. ncbi Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors
    Ingrid T G W Bijsmans
    Department of Pathology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    Mod Pathol 24:463-70. 2011
    ....
  39. ncbi Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response
    Kim M Smits
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, The Netherlands
    Pharmacogenomics 9:1903-16. 2008
    ..This review describes the current knowledge on the prognostic and predictive value of epigenetic markers in colorectal cancer...
  40. ncbi The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications
    Veerle Melotte
    Department of Pathology, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
    FASEB J 24:4153-66. 2010
    ..Finally, their role in disease and potential clinical applications (their role as detection or prognostic markers) are discussed...
  41. ncbi Molecular tests for colorectal cancer screening
    Linda J W Bosch
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Colorectal Cancer 10:8-23. 2011
    ..Evaluation in large well-controlled randomized trials is the next step needed to take molecular markers for CRC screening to the next level and warrant implementation in a screening setting...
  42. ncbi Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis
    Laura A E Hughes
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Int J Epidemiol 41:1060-72. 2012
    ..We investigated whether measures of anthropometry differentially influence risk of tumours according to BRAF c.1799T>A p.V600E mutation (BRAF) and microsatellite instability (MSI) status...
  43. ncbi Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components
    Tjinta Brinkhuizen
    Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands
    PLoS ONE 7:e51710. 2012
    ..Epigenetic alterations such as promoter hypermethylation silence tumor suppressor genes (TSG) in several malignancies...
  44. ncbi Genetics and epigenetics of renal cell cancer
    Marcella M L Baldewijns
    Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Biochim Biophys Acta 1785:133-55. 2008
    ..In this review we discuss the background of RCC and the clinical applications of RCC genetics and epigenetics...
  45. ncbi Angiostatic activity of DNA methyltransferase inhibitors
    Debby M E I Hellebrekers
    Angiogenesis Laboratory, Research Institute for Growth and Development, Department of Pathology, Maastricht University and University Hospital, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
    Mol Cancer Ther 5:467-75. 2006
    ..In conclusion, our data show that DNMT inhibitors have angiostatic activity in addition to their inhibitory effects on tumor cells. This dual action of these compounds makes them promising anticancer therapeutics...
  46. ncbi Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors
    Nathalie L G Sieben
    Department of Pathology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands
    J Clin Oncol 23:7257-64. 2005
    ..The purpose of this study was to further unravel the genetic pathways through which SBTs develop, with a special focus on explaining the generally benign SBT behavior. Materials and..
  47. ncbi Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune
    Karin van den Hurk
    Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands
    Biochim Biophys Acta 1826:89-102. 2012
    ..Importantly, we point out that it is this interplay of genetics and epigenetics that effectively leads to distorted gene expression patterns in CMM...
  48. ncbi Taxane resistance in breast cancer: a closed HER2 circuit?
    Joep P J de Hoon
    Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands
    Biochim Biophys Acta 1825:197-206. 2012
    ..In conclusion, taxane resistance in breast cancer follows a multiplex establishment of drug cytotoxicity escape routes, which may be most efficiently therapeutically targeted by interference with their mutually governing signaling nodes...
  49. ncbi Characteristics of triple-negative breast cancer
    Tim C de Ruijter
    Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, P O Box 5800, 6202 AZ Maastricht, The Netherlands
    J Cancer Res Clin Oncol 137:183-92. 2011
    ..The purpose of this review is to summarise the latest findings on TNBC concerning its relation and delineation to BBC, discuss the developmental pathways involved and address clinical implications for this complex type of breast cancer...
  50. ncbi K-ras mutations and RASSF1A promoter methylation in colorectal cancer
    Manon van Engeland
    Department of Pathology, University Maastricht, P O Box 616 6200 MD Maastricht, The Netherlands
    Oncogene 21:3792-5. 2002
    ..These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chi-square test)...